Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer

DSpace/Manakin Repository

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer

Citable link to this page

 

 
Title: Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer
Author: Oran, Amanda R.; Adams, Clare M.; Zhang, Xiao-yong; Gennaro, Victoria J.; Pfeiffer, Harla K.; Mellert, Hestia S.; Seidel, Hans E.; Mascioli, Kirsten; Kaplan, Jordan; Gaballa, Mahmoud R.; Shen, Chen; Rigoutsos, Isidore; King, Michael P.; Cotney, Justin L.; Arnold, Jamie J.; Sharma, Suresh D.; Martinez, Ubaldo E.; Vakoc, Christopher R.; Chodosh, Lewis A.; Thompson, James E.; Bradner, James E.; Cameron, Craig E.; Shadel, Gerald S.; Eischen, Christine M.; McMahon, Steven B.

Note: Order does not necessarily reflect citation order of authors.

Citation: Oran, A. R., C. M. Adams, X. Zhang, V. J. Gennaro, H. K. Pfeiffer, H. S. Mellert, H. E. Seidel, et al. 2016. “Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.” Oncotarget 7 (45): 72395-72414. doi:10.18632/oncotarget.11718. http://dx.doi.org/10.18632/oncotarget.11718.
Full Text & Related Files:
Abstract: Despite ubiquitous activation in human cancer, essential downstream effector pathways of the MYC transcription factor have been difficult to define and target. Using a structure/function-based approach, we identified the mitochondrial RNA polymerase (POLRMT) locus as a critical downstream target of MYC. The multifunctional POLRMT enzyme controls mitochondrial gene expression, a process required both for mitochondrial function and mitochondrial biogenesis. We further demonstrate that inhibition of this newly defined MYC effector pathway causes robust and selective tumor cell apoptosis, via an acute, checkpoint-like mechanism linked to aberrant electron transport chain complex assembly and mitochondrial reactive oxygen species (ROS) production. Fortuitously, MYC-dependent tumor cell death can be induced by inhibiting the mitochondrial gene expression pathway using a variety of strategies, including treatment with FDA-approved antibiotics. In vivo studies using a mouse model of Burkitt's Lymphoma provide pre-clinical evidence that these antibiotics can successfully block progression of MYC-dependent tumors.
Published Version: doi:10.18632/oncotarget.11718
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340124/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071988
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters